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High-Dose Resveratrol Supplementation in Obese Men
An Investigator-Initiated, Randomized, Placebo-Controlled
Clinical Trial of Substrate Metabolism, Insulin Sensitivity,
and Body Composition
Morten M. Poulsen,1 Poul F. Vestergaard,1 Berthil F. Clasen,1 Yulia Radko,2
Lars P. Christensen,2 Hans Stødkilde-Jørgensen,3 Niels Møller,1 Niels Jessen,4 Steen B. Pedersen,1
and Jens Otto L. Jørgensen1
Obesity, diabetes, hypertension, and hyperlipidemia constitute
risk factors for morbidity and premature mortality. Based on
animal and in vitro studies, resveratrol reverts these risk factors
via stimulation of silent mating type information regulation 2
homolog 1 (SIRT1), but data in human subjects are scarce. The
objective of this study was to examine the metabolic effects of
high-dose resveratrol in obese human subjects. In a randomized,
placebo-controlled, double-blinded, and parallel-group design,
24 obese but otherwise healthy men were randomly assigned to
4 weeks of resveratrol or placebo treatment. Extensive meta-
bolic examinations including assessment of glucose turnover and
insulin sensitivity (hyperinsulinemic euglycemic clamp) were
performed before and after the treatment. Insulin sensitivity, the
primary outcome measure, deteriorated insigniﬁcantly in both
groups. Endogenous glucose production and the turnover and
oxidation rates of glucose remained unchanged. Resveratrol sup-
plementation also had no effect on blood pressure; resting energy
expenditure; oxidation rates of lipid; ectopic or visceral fat
content; or inﬂammatory and metabolic biomarkers. The lack of
effect disagrees with persuasive data obtained from rodent mod-
els and raises doubt about the justiﬁcation of resveratrol as a
human nutritional supplement in metabolic disorders. Diabetes
62:1186–1195, 2013
Management of obesity and its complications isa major health issue (1). Because primarypreventive measures often fail and therapeu-tic options are insufﬁcient, novel treatment
modalities are being investigated (2). As such, the poly-
phenolic compound resveratrol has attracted attention
over the past decades (3). It is widely distributed in nature
and plays an important role in plants’ defenses against
external stressors and infections; it also is a constituent of
grapes and wine, albeit in minute amounts (on average, 1.9
mg/L in red wine) (4).
Preclinical trials suggest that resveratrol mimics the
metabolic effects of calorie restriction (CR) (5) via acti-
vation of silent mating type information regulation 2 ho-
molog 1 (SIRT1) (6–9). By means of NAD+-dependent
deacetylase activity, SIRT1 modiﬁes various target pro-
teins, in particular transcription factors critical for energy
metabolism, such as nuclear factor-kB, peroxisome pro-
liferator-activated receptor g coactivator 1-a, forkhead
transcription factor class O, and sterol regulatory element-
binding protein 1 (10,11).
In experimental animals, these effects translate into
improved glucose metabolism (5,7,12–14), reduced in-
ﬂammation (15–17), cancer prevention (18–21), reversal
of nonalcoholic fatty liver disease (7,17,22–24), and pre-
vention of obesity (8,25) In accordance with CR, supple-
mentation with resveratrol promotes longevity in several
primitive species (26–28) and protects against diet-induced
metabolic abnormalities in rodents (7). Whether these
effects of resveratrol apply to human beings remains un-
certain, even though it is widely distributed as an over-the-
counter nutritional supplement.
Only one trial systematically examining metabolic
effects has been performed in humans: 11 obese male par-
ticipants received a daily dose of 150 mg resveratrol or
placebo for 30 days in a double-blind crossover design.
Signiﬁcant albeit moderate improvements in insulin sensi-
tivity, blood pressure, metabolic rate, hepatic steatosis, and
pertinent biomarkers were recorded (29). Apart from this
single study, only a limited number of human clinical trials
of efﬁcacy outcomes have been conducted (30–32). In the
present study we tested the impact of high-dose resveratrol
administration for 4 weeks on energy and substrate me-
tabolism, insulin sensitivity, ectopic fat disposition, 24-h
ambulatory blood pressure, and inﬂammatory as well as
metabolic biomarkers in obese human subjects.
RESEARCH DESIGN AND METHODS
Ethical approval. All participants were given oral and written information
before written informed consent was obtained. The protocol was approved
by the Regional Committee on Health Research Ethics and the Danish Data
Protection Agency, and the study was conducted in agreement with the Dec-
laration of Helsinki II. According to the International Committee of Medical
Journal Editors, the protocol was registered at clinicaltrials.gov (NCT01150955)
before recruitment was initiated.
Subjects. Twenty-four male volunteers, aged 18–70 years, participated. All
participants were obese (BMI .30 kg/m2) but otherwise healthy, were taking
no prescriptive medicine, and had no overt endocrine disorders. Eligibility
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ultimately was based on a normal physical examination including routine
clinical biochemistry and electrocardiography.
Study design. The study was an investigator-initiated randomized, double-
blinded, placebo-controlled, parallel-group trial. The subjects were treated for
4 weeks with tablets containing 500 mg trans-resveratrol (Fluxome Inc.,
Stenlose, Denmark) or placebo (Robinson Pharma, Santa Ana, CA) thrice
daily. Randomization, blinding, packaging, and labeling was performed by the
pharmacy at Aarhus University Hospital. The randomization code was un-
blinded once all predeﬁned data were recorded.
During the trial period, the subjects were instructed to abstain from using
nutritional supplements and consuming food suspected to contain resveratrol
in signiﬁcant amounts. Furthermore, the importance of maintaining their
normal way of living was underscored. The compliance rate, deﬁned as the
proportion of tablets ingested relative to the intended number, was calculated
when participants returned the remaining tablets during the last examination.
Overall visits and interventions. Examinations were performed on 3 con-
secutive days both at baseline and after 4 weeks of treatment with the same
equipment and by the same physicians and laboratory technicians on both
occasions.
On the ﬁrst day we performed dual-energy X-ray absorptiometry scan and
initiated 24-h ambulatory blood pressure recordings. On the second day, we
conducted magnetic resonance (MR) spectroscopy and imaging, and on the
third day and after an overnight fast the participants underwent a full-day
metabolic investigation including a hyperinsulinemic euglycemic clamp with
continuous infusion of a primed glucose tracer, indirect calorimetry, repetitive
blood sampling, and muscle and adipose tissue biopsies.
When completing the full-day metabolic investigation at baseline, the tablets
were provided and the subjects were instructed to initiate tablet consumption
in the evening and subsequently three times daily until the overnight fast before
the third examination day at week 4. At weeks 2, 4, and 6, potential adverse
events were recorded, and fasting blood samples were drawn for safety pur-
poses. Urine from the ﬁrst void was collected for pharmacokinetic purposes in
the morning of the third examination day at week 4.
Hyperinsulinemic euglycemic clamp. After an overnight fast (from 10:00 P.M.),
the participants presented to the research unit at 7.30 A.M. and were studied in
the supine position during thermoneutral conditions in the fasting state for 6 h.
For the purpose of infusions, a catheter (Venﬂon; Viggo, Helsingborg,
Sweden) was inserted into the antecubital vein. Another catheter was placed in
a heated dorsal hand vein for sampling of arterialized blood. Samples were
drawn at 0, 160, 170, 180, 340, 350 and 360 min; while the clamp was in place,
plasma glucose levels were determined every 10 min.
The participants were studied from 8:00 A.M. to 2:00 P.M. (0–360 min)
(Supplementary Fig. 1). After a 3-h basal period (0–180 min), they were
clamped at a blood glucose level of 5 mmol/L with a 0.5 mU/kg/min insulin
infusion (Actrapid; Novo Nordisk, Bagsværd, Denmark) for the last 3 h (180–
360 min) by adjusting the infusion rate of 20% glucose (GIR) in response to
blood glucose measurements every 10 min. After emptying the bladder at
0 min, urine was collected at the end of both the basal and clamp periods and
the volume was measured.
Muscle and adipose tissue biopsies. Under sterile conditions and using local
anesthesia (Lidocaine SAD 10mg/mL; Amgros, Copenhagen, Denmark) skeletal
muscle and adipose tissue biopsies were taken at the end of the basal period
and 20 min into the clamp period (140 and 200 min, respectively). The muscle
biopsy was obtained from the vastus lateralis muscle using a Bergström biopsy
needle. The muscle tissue was immediately dissected free from fat and con-
nective tissue and transferred to liquid nitrogen. Subcutaneous abdominal fat
was obtained by liposuction 15 cm lateral to the umbilicus, cleaned, and
subsequently snap-frozen in liquid nitrogen.
[3-3H]-glucose tracer. A primed continuous infusion of [3-3H]-glucose was
given during the entire 6-h basal/clamp procedure (bolus 20 mCi followed by
0.19 mCi/min; NEN Life Science Products, Boston, MA). To avoid rapid dilution
of [3-3H]-glucose during the hyperinsulinemic euglycemic clamp, [3-3H]-
glucose was added to the infused glucose (100 mCi [3-3H]-glucose/500 ml
20% glucose).
Speciﬁc activity of [3-3H]-glucose was measured (33), and glucose rate of
appearance (Ra) and rate of disappearance (Rd) was calculated at 10-min
intervals from 150 to 180 and 330 to 360 min using Steele’s non-steady-state
equation (34).
Under basal conditions, the endogenous glucose production (EGP) equals
Ra, and during the clamp period, EGP is calculated by subtracting the mean
GIR from Ra. Nonoxidative glucose disposal is derived by subtracting oxida-
tive glucose disposal from total glucose disposal (Rd).
Indirect calorimetry. The respiratory quotient (RQ) and resting energy ex-
penditure (REE) were estimated by indirect calorimetry (Deltatrac; Datex-
Ohmeda, Helsinki, Finland) performed at 90–120 min and 270–300 min in the
basal and clamp periods, respectively. Mean values taken during the last
25 min were used for calculations. Glucose and lipid oxidation rates were
estimated after correction for protein oxidation, which was calculated on the
basis of urea nitrogen excretion (35). Urinary urea content was measured
by absorption photometry (ROCHE cobas 6000C, Roche Applied Science,
Penzberg, Germany).
Blood sampling and analysis. Plasma glucose was measured in duplicate
immediately after sampling on an YSI 2300 Stat Plus (YSI Inc., Yellow Springs,
OH). Glycated hemoglobin (HbA1c), alanine aminotranferase, and leukocytes
were analyzed at the University Hospital Department of Clinical Biochemistry
using standard methods. All other parameters were analyzed on serum that
had been frozen and stored (280°C) immediately after being drawn and
centrifuged.
Total cholesterol, HDL, and triglycerides were determined by absorption
photometry (ROCHE cobas 6000C, Roche Applied Science), and LDL sub-
sequently was calculated using the Friedewald formula (36).
Insulin was analyzed using time-resolved immunoﬂuorometric assay
(AutoDELFIA Insulin kit, catalog no. B080–101, PerkinElmer, Turku, Finland)
and free fatty acids (FFAs) by a commercially available kit (Wako Chemicals,
Neuss, Germany). Glucagon and adiponectin were measured by in-house ra-
dioimmunoassay (37) and time-resolved immunoﬂuorometric assay (38), re-
spectively.
Finally, C-peptide (DakoCytomation, Cambridgeshire, UK); cortisol (Cor-
tisol ELISA, DRG Instruments GmbH, Marburg, Germany); interleukin 6 (Hu-
man IL-6 Quantikine HS ELISA Kit [HS600B], R&D Systems, Minneapolis, MN);
monocyte chemoattractant protein-1 (Human CCL2/MCP-1 Quantikine ELISA
Kit (DCP00), R&D Systems); tumor necrosis factor a (Human TNF-a Quanti-
kine HS ELISA [HSTA00D], R&D Systems); high-sensitivity C-reactive protein
(CRP High Sensitive ELISA (EIA-3954), AH Diagnostics, Aarhus, Denmark);
and leptin (Leptin ELISA E07, Mediagnost, Reutlingen, Germany) were ana-
lyzed using commercially available ELISA kits.
Hormones relevant to the clamp procedure (C-peptide, FFA, insulin, cor-
tisol, adiponectin, glucagon) were measured at 0, 160, 170, 180, 340, 350,
and 360 min and expressed as mean values of basal and clamp triplicates,
respectively; the remainder were measured at 0 min. Homeostasis model
assessment–insulin resistance (HOMA-IR) was calculated using the standard
formula (39), based on fasting glucose and insulin.
Magnetic resonance spectroscopy and imaging. Intrahepatic and intra-
myocellular fat content as well as visceral (VAT) and subcutaneous abdominal
adipose tissue (SAAT) volumes were measured with magnetic resonance (MR)
techniques using a Signa Excite 1.5 Tesla twin-speed scanner (GE Medical
Systems, GE Healthcare, Little Chalfont, U.K.). MR spectroscopy of the skeletal
muscle included a point-resolved spectroscopy sequence (water suppression;
echo time 27 ms; repetition time 3000 ms) on a 23 23 2 cm voxel positioned in
the largest cross-sectional area of the tibialis anterior muscle. Full width at
half maximum was 13.4 6 2.2 Hz. The 1H-MR liver spectroscopy technique has
been described previously (40); full width at half maximum was 13.7 6 3.3 Hz.
The spectra were quantiﬁed by using the LCmodel software package (version
6.2; Stephen Provencher) by means of a dedicated muscle and liver spec-
troscopy ﬁtting model. The data processing provided an estimate of the ratio
of lipid to water in the tissue within the voxel (41). VAT and SAAT volumes
were quantiﬁed by MR imaging (body coil; fast-spin echo sequence; echo time
8.5 ms; repetition time 600 ms; slice thickness 8 mm; ﬁeld of view 48 cm). On
the basis of repetitive axial slices from the proximal border of the left kidney
to the femur neck, data processing was done using the software package
Hippofat (42).
Dual-energy X-ray absorptiometry. Whole-body bone mineral density and
body composition were assessed by dual-energy X-ray absorptiometry (Hologic
Discovery scanner S/N 80027; Hologic Inc., Waltham, MA).
Blood pressure. Noninvasive, 24-h, ambulatory blood pressure monitoring
was performed based on measurements every 20th minute (Spacelabs, model
90217).
Western blotting. Frozen muscles biopsies (;30 mg) were homogenized in
ice-cold solubilization buffer (43), and samples were rotated for 60 min at 4°C.
Insoluble materials were removed by centrifugation at 16,000g for 20 min at 4°C,
and the protein content of the protein-containing supernatant was determined.
Aliquots of protein were resolved by SDS-PAGE, transferred to poly-
vinylidene ﬂuoride membranes, and incubated with primary antibody. All
primary antibodies were from Cell Signaling (Beverly, MA). To determine
relative phosphorylation levels, phospho-speciﬁc blots were stripped in SDS
buffer and reprobed with the primary antibody for the detection. Horseradish
peroxidase-conjugated goat antirabbit immunoglobulin G antibody (Amer-
sham, GE-Healthcare, Pittsburgh, PA) was used as the secondary antibody.
Proteins were visualized by enhanced chemiluminescence (Pierce Supersignal
West Dura; Thermo Scientiﬁc, Rockford, IL) using a ChemiDoc XRS+ CCD
camera (BioRad, Hercules, CA).
Real-time RT-PCR. Total RNA was isolated from muscle and adipose tissue
using Trizol (Gibco BRL, Life Technologies, Roskilde, Denmark); RNA was
quantiﬁed by measuring absorbance at 260 and 280 nm with a ratio $1.8 using
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a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientiﬁc Inc., Waltham,
MA). Integrity of the RNA was checked by visual inspection of the two ribo-
somal RNAs (18S and 28S) on an agarose gel. cDNA was synthesized with the
Verso cDNA kit AB 1453 (Thermo Fisher Scientiﬁc Inc.) using random hex-
amers. Real-time PCR for target genes was done with b2-microglobulin levels
as the internal control, and this expression did not change during intervention.
Sequences of the primers used are given in Supplementary Table 1.
The PCR reactions were performed in duplicate using the KAPA SYBR FAST
qPCR kit (Kapa Biosystems, Inc., Woburn, MA) in a LightCycler 480 (Roche
Applied Science) using the following protocol: One step at 95°C for 3 min, then
95°C for 10 s, 60°C for 20 s, and 72°C for 10 s. The increase in ﬂuorescence was
measured in real time during the extension step. The relative gene expression
was estimated using the default “Advanced Relative Quantiﬁcation” mode of
the software version LCS 480 1.5.0.39 (Roche Applied Science).
Plasma pharmacokinetics and urine metabolite identiﬁcation. Concen-
trations of urinary resveratrol metabolites were determined by high-perfor-
mance liquid chromatography (HPLC) with ultraviolet/visible detection
according to the following method: Aliquots of 2 mL urine were loaded onto
conditioned polyamide solid phase extraction cartridges (180 mg), which were
washed with 10 mL of water and 5 mL of methanol. The organic layer was
evaporated to dryness, and the residues dissolved in 200 mL of 80% acetonitrile
before 10 mL was injected for HPLC analysis.
Plasma samples (200 mL) were extracted with 500 mL acetonitrile (100%),
mixed, and centrifuged for 3 min at 10,000 rpm. The supernatant was evapo-
rated and redissolved in 200 mL acetonitrile (10%), and 10 mL was injected for
HPLC analysis.
Metabolites were separated using aqueous ammonium formate (10 mmol/L;
pH = 8.2) or aqueous formic acid (0.1%; pH 2.5) as solvent A and acetonitrile as
solvent B in the mobile phase (ﬂow rate 0.5 mL/min) with the following gra-
dient: 10%B linear (0–10 min), 10–40%B linear (10–40 min), 40–99%B linear
(40–43 min), 99%B linear (43–48 min). A HyperClone C18 reverse-phase column
(length 150 mm, internal diameter4.6 mm, particle size 3 mm; Phenomenex,
Torrance, CA) protected by precolumn was used. Detection of metabolites was
performed at l = 300 nm. All metabolites were quantiﬁed by external standard
calibration. Recoveries of resveratrol were measured by spiking blank urine and
plasma samples at the ﬁnal concentration: from 7.8 mg/mL to 500 mg/mL for urine
and from 0.01 mg/mL to 0.05 mg/mL for plasma. Metabolite equivalents were
recalculated using standard calibration curves for resveratrol. The structures of
metabolites were interpreted by negative atmospheric pressure chemical ioni-
zation liquid chromatography–mass spectrometry/mass spectrometry under the
HPLC conditions described earlier; these experiments were performed on an
LTQ XL (Thermo Fisher Scientiﬁc).
Statistical analysis. Results are presented as means 6 SEM when normally
distributed and median (range) when not. Unless otherwise noted, the main
treatment comparisons between the two groups were assessed by two-way
repeated-measures ANOVA. Normality was checked by QQ-plots, and test for
equal variance was assessed by the Levene’s test for equal variances. If
skewed, the data were logarithmically transformed before applying ANOVA.
When revealing signiﬁcant differences, post hoc pairwise multiple comparison
procedures were performed using the Student-Newman-Keuls method.
When appropriate, one-way ANOVA was used on normally distributed data,
and the Kruskal-Wallis one-way ANOVA on ranks was used when they were
not normally distributed. Baseline comparisons were done by unpaired Stu-
dent t test. Before applying a nonparametric test, the data were logarithmically
transformed. If the data were normally distributed, the unpaired Student t test
was used. If the data were not normally distributed, the Mann-Whitney rank
sum test was used.
TABLE 1
Baseline characteristics
Characteristics Placebo Resveratrol P value
Age (years) 31.9 6 2.9 44.7 6 3.5 0.01
Weight (kg) 115.9 6 3.6 107.1 6 2.7 0.065
BMI (kg/m2) 35.9 6 1.2 32.5 6 0.6 0.053
Lean mass (kg) 73.4 6 1.8 69.1 6 1.6 0.083
Fat mass (kg) 37.0 6 2.6 31.7 6 1.4 0.078
Fat (%) 32.3 6 1.4 30.2 6 0.7 0.37
Visceral fat
volume (cm3) 4285 6 585 4996 6 876 0.51
Abdominal
subcutaneous
fat volume (cm3) 10737 6 1086 8103 6 585 0.051
Systolic blood
pressure (mmHg) 126.1 6 2.3 124.3 6 2.9 0.64
Diastolic blood
pressure (mmHg) 74.4 6 1.6 75.6 6 2.1 0.61
Glucose (mmol/L) 5.3 6 0.1 5.6 6 0.1 0.18
HbA1c (%) 5.6 6 0.1 5.6 6 0.1 0.55
Total cholesterol
(mmol/L) 5.3 6 0.4 5.5 6 0.3 0.65
HDL cholesterol
(mmol/L) 0.9 6 0.1 1.0 6 0.1 0.84
LDL cholesterol
(mmol/L) 3.2 6 0.2 3.6 6 0.2 0.22
Triglycerides (mmol/L) 2.0 6 0.3 2.0 6 0.3 0.97
Twenty-four volunteers were randomly assigned 4 weeks of placebo
(n = 12) or resveratrol (n = 12) treatment. Values are shown as
means 6 SEM.
TABLE 2
Plasma biochemisty
Placebo Resveratrol
P value*Before After Before After
Glucose (mmol/L) 5.33 6 0.08 5.33 6 0.13 5.55 6 0.14 5.55 6 0.10 1.00
Insulin (pmol/L) 79.8 6 10.4 79.9 6 5.7 67.8 6 7.8 71.0 6 12.0 0.80
HOMA-IR index 3.17 6 0.44 3.19 6 0.27 2.78 6 0.34 2.94 6 0.52 0.82
HbA1c (%) 5.56 6 0.05 5.42 6 0.05 5.61 6 0.06 5.52 6 0.05 0.33
Cholesterol (mmol/L) 5.27 6 0.35 5.13 6 0.21 5.47 6 0.56 5.67 6 0.24 0.27
HDL (mmol/L) 0.93 6 0.06 1.02 6 0.06 0.95 6 0.07 0.94 6 0.07 0.13
LDL (mmol/L) 3.19 6 0.22 3.03 6 0.17 3.59 6 0.24 3.77 6 0.23 0.22
Triglycerides (mmol/L) 2.03 6 0.33 2.18 6 0.29 2.04 6 0.28 2.12 6 0.28 0.80
Leptin (ng/mL) 19.47 6 3.95 18.00 6 1.98 18.80 6 3.54 22.97 6 6.65 0.32
hsCRP (ng/mL) 2.86 6 0.39 4.04 6 1.01 4.04 6 0.73 4.58 6 0.91 0.63
IL-6 (pg/mL) 3.21 6 0.96 3.59 6 0.72 4.84 6 1.07 4.50 6 0.77 0.60
TNF-a (pg/mL) 4.69 6 0.79 5.00 6 1.70 4.24 6 0.84 4.14 6 1.00 0.82
MCP-1 (pg/mL) 140.1 6 7.5 134.2 6 8.4 159.5 6 10.7 178.4 6 15.9 0.13
Leukocytes (109/L) 5.98 6 0.45 6.71 6 0.58 6.23 6 0.48 5.87 6 0.35 0.94
ALT (U/L) 48.5 6 5.4 54.6 6 6.7 47.7 6 10.2 46.9 6 8.7 0.10
Circulating parameters before and after 4 weeks’ treatment with placebo (n = 12) or resveratrol (n = 12). All data are presented as means6
SEM. HOMA-IR, homeostasis model assessment–insulin resistance; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; TNF, tumor
necrosis factor; MCP-1, monocyte chemoattractant protein 1; ALT, alanine aminotransferase. *P values reﬂect overall comparison of the
groups by two-way repeated-measures ANOVA.
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Within-group comparisons were analyzed by paired t test or Wilcoxon
signed rank test. P values ,0.05 were considered signiﬁcant. Power calcu-
lations were based on changes in M value. To detect a treatment difference of
1.0 mg/kg/min at a two-sided 0.05 signiﬁcance level with a power of 0.90, nine
participants had to be included in each group, assuming an SD of 0.6.
RESULTS
Baseline and internal validity. A total of 26 subjects
were enrolled, but one participant dropped out because of
claustrophobia in relation to MR imaging, and another
developed a generalized rash after 1 week and was ex-
cluded (Supplementary Fig. 2). Both placebo and resver-
atrol tablets were generally well tolerated (Supplementary
Table 2). The compliance rates, based on pill count, were
89.2 6 2.9% and 88.9 6 3.3% in the placebo and resveratrol
groups, respectively. By chance the two groups differed
slightly in mean age but were comparable on all other
baseline parameters (Table 1).
To document systemic absorption of the investigational
product, we did a pharmacokinetic pilot study before the
clinical trial. In that pilot study, three healthy subjects
ingested one resveratrol tablet (from the same batch as
the investigational product) of 500 mg followed by
plasma samples at 0, 15, 30, 45, 60, 90, 120, 180, 240,
and 300 min. The native compound reached traceable
amounts at 15 min, and Cmax was reached at 90 min with
300–400 ng/mL, which is consistent with the literature
(Supplementary Fig. 3) (44–48) yet distinctly below the
concentration usually described in in vitro studies (50
mmol/L  11,400 ng/mL) (8). Furthermore, we compared
the absorption proﬁle of our investigational product
(trans-resveratrol, Fluxome Inc., Stenlose, Denmark)
with that of a similar product (500 mg resVida, DSM
Nutritional Products, Ltd., Kaiseraugst, Switzerland).
The two products exhibited similar absorption proﬁles
(Supplementary Fig. 3).
The level of urinary resveratrol metabolites was de-
termined at week 4, and no metabolites were detected in
the placebo group, whereas measurable amounts were
found in the resveratrol group (Supplementary Table 3).
TABLE 3
Substrate metabolism and circulating hormones
Placebo Resveratrol
Before After Before After
Glucose oxidation (mg/kg/min)
Basal 1.09 6 0.11 1.28 6 0.13 1.21 6 0.16 1.13 6 0.12
Clamp 1.15 6 0.12 1.32 6 0.09 1.30 6 0.12 1.35 6 0.13
Protein oxidation (mg/kg/min)
Basal 0.62 6 0.08 0.50 6 0.08 0.57 6 0.06 0.62 6 0.06
Clamp 0.82 6 0.09 0.64 6 0.06* 0.60 6 0.07 0.62 6 0.05
Lipid oxidation (mg/kg/min)
Basal 0.58 6 0.05 0.58 6 0.06 0.56 6 0.07 0.56 6 0.05
Clamp 0.44 6 0.04* 0.48 6 0.04* 0.51 6 0.07 0.49 6 0.06
Resting energy expenditure (kcal/24 h)
Basal 2143 6 128 2170 6 116 1955 6 183 1949 6 151
Clamp 2125 6 135 2144 6 106 1959 6 164 1980 6 143
Respiratory quotient (%)
Basal 0.83 6 0.01 0.84 6 0.01 0.84 6 0.01 0.84 6 0.01
Clamp 0.85 6 0.01 0.85 6 0.01 0.85 6 0.01 0.85 6 0.01
Insulin (pmol/L)
Basal 79.9 6 10.4 79.8 6 5.7 67.8 6 7.8 71.0 6 12.0
Clamp 327.3 6 16.2* 348.6 6 18.2* 298.7 6 16.9* 289.8 6 17.1*
C-peptide (pmol/L)
Basal 1049 6 68 1041 6 43 1042 6 67 1051 6 90
Clamp 790 6 73* 859 6 75* 597 6 60* 630 6 61*
Glucagon (pg/mL)
Basal 71.8 6 10.9 74.4 6 8.6 69.2 6 14.0 69.1 6 10.0
Clamp 30.3 6 3.2* 32.3 6 3.9* 35.9 6 3.3* 39.3 6 7.1*
Cortisol (ng/mL)
Basal 80.2 6 14.0 78.8 6 12.3 100.5 6 12.5 88.6 6 16.0
Clamp 65.8 6 7.9 70.5 6 6.6 73.0 6 7.7 89.4 6 11.2
Adiponectin (mg/L)
Basal 6.09 6 0.65 6.65 6 0.71 6.71 6 0.74 6.93 6 0.74
Clamp 5.94 6 0.64 6.45 6 0.67* 6.48 6 0.72* 6.73 6 0.73*
FFA (mmol/L)
Basal 0.46 6 0.04 0.43 6 0.03 0.42 6 0.03 0.49 6 0.05
Clamp 0.087 6 0.011* 0.084 6 0.014* 0.099 6 0.016* 0.109 6 0.024*
Major markers of substrate metabolism were assessed with (clamp period) and without (basal period) insulin stimulation before and after 4
weeks’ treatment with placebo (n = 12) or resveratrol (n = 12). The respiratory quotient and resting energy expenditure were estimated by
indirect calorimetry. Glucose and lipid oxidation rates were calculated after correction for protein oxidation, which was estimated on the
basis of urea nitrogen excretion. The presented circulating parameters were measured in triplicates at the end of the basal (160, 170, 180 min)
and clamp (340, 350, 360 min) periods, respectively. The overall treatment effect was evaluated by two-way repeated-measures ANOVA or
one-way ANOVA when relevant. All treatment comparisons were performed in the basal and clamp situations. No signiﬁcant differences
occurred due to the intervention. All data are presented as means 6 SEM. *A statistically signiﬁcant within-group effect (P ,0.05) of the
insulin stimulation evaluated by a paired t test (i.e., basal vs. clamp).
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Clinical biochemistry.We recorded no signiﬁcant effects
of resveratrol on HbA1c levels or the HOMA-IR. At base-
line, the lipid proﬁle was abnormal and compatible with
obesity, but we observed no changes in total cholesterol,
HDL, LDL, or triglycerides during the intervention period.
Moreover, we did not record signiﬁcant deviations in any
inﬂammatory biomarkers, leptin, or liver function tests
(Table 2).
Substrate metabolism. We did not record statistically
signiﬁcant changes in resting energy expenditure or res-
piratory quotient or in glucose or lipid oxidation rates
when comparing basal and clamp values between the
groups (Table 3). As expected, glucose oxidation in-
creased during the clamp at the expense of reduced lipid
oxidation. However, these changes did not differ either
between or within the two groups (Table 3).
We also failed to detect signiﬁcant differences in insu-
lin, C-peptide, glucagon, cortisol, adiponectin, or FFAs be-
tween the groups. We recorded a signiﬁcant within-group
suppression of C-peptide, glucagon, and FFA levels during
the clamp studies both before and after the intervention.
We also found a statistically signiﬁcant and expected de-
crease in insulin stimulated adiponectin. No within-group
changes in cortisol levels were found during insulin stim-
ulation (Table 3).
Insulin sensitivity. Insulin sensitivity assessed by the
hyperinsulinemic euglycemic clamp method was not sig-
niﬁcantly affected by resveratrol. Insulin levels increased
from 75 pmol/L in the basal period to 315 pmol/L in the
clamp period, with no signiﬁcant differences between the
groups regarding the overall basal and clamp periods (P =
0.66 and P = 0.07, respectively). As depicted in Fig. 1A and
B, the GIR increased during the clamp and plateaued
FIG. 1. Insulin sensitivity and glucose metabolism. Glucose metabolism was examined before and after 4 weeks of resveratrol or placebo sup-
plementation. Black bars and black dots indicate placebo group (n = 12) and white bars and white dots indicate the resveratrol group (n = 12).
Results are presented as group means 6 SEM. Insulin sensitivity was assessed by a hyperinsulinemic euglycemic clamp. The participants were
clamped at a blood glucose level of ;5 mmol/L with an insulin infusion of 0.5 mU/kg/min. A and B: The GIR before and after intervention, re-
spectively. P values reﬂect between-group differences assessed by two-way repeated-measures ANOVA. C: The corresponding whole-body insulin
sensitivity, the M value, deﬁned as the mean GIR during the last 30 min of the clamp. P value reﬂects the potential treatment effect analyzed by
two-way repeated-measures ANOVA. D: Glucose Rd. E: EGP. F: Nonoxidative glucose disposal. *A statistically signiﬁcant within-group effect of the
insulin stimulation evaluated by a paired t test. Overall comparisons of potential treatment effects were performed by two-way repeated-measures
ANOVA in the basal and clamp situations, respectively. NS, nonsigniﬁcant.
FIG. 2. Blood pressure. Ambulatory blood pressure was measured auto-
matically by a portable device every 20th minute over 24 h. Results are
presented as box plots of the absolute changes from baseline after 4 weeks
of placebo (n = 12) or resveratrol (n = 12) supplementation, respectively.
The box boundaries indicate the 25th–75th percentile range, and error
bars represent the 5th–95th percentiles. Solid and dotted lines represent
median and mean, respectively. Resveratrol supplementation tends to in-
crease both systolic and diastolic blood pressure; however, the elevations
are not signiﬁcant when compared with the placebo group by two-way
repeated-measures ANOVA (systolic, P = 0.39; diastolic, P = 0.36).
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toward the end of the clamp. GIR did not differ between
the groups, and the corresponding M value, deﬁned as the
mean GIR during the last 30 min of the clamp, also was
comparable between the groups (Fig. 1C). As expected,
insulin increased the glucose Rd approximately threefold
in the clamp situation compared with the basal condition
in all experimental settings, with no signiﬁcant differences
between the two groups (Fig. 1D). Likewise, EGP during
both the basal state and the clamp period was comparable
between the two groups (Fig. 1E). Finally, the rates of
oxidative as well as nonoxidative glucose disposal did not
differ between the groups (Fig. 1F).
FIG. 3. Body composition. Absolute changes in essential body composition parameters after 4 weeks of placebo (n = 12) or resveratrol supple-
mentation (n = 12). The box boundaries indicate the 25th–75th percentile range, and error bars represent the 5th–95th percentiles. Solid and
dotted lines represent median and mean, respectively. A–D were assessed by whole-body dual-energy X-ray absorptiometry; E and F were quan-
tiﬁed by MR imaging based on repetitive axial slices from the proximal border of the left kidney to the femur neck; nine were evaluable in each
group. Two-way repeated-measures ANOVA revealed no statistically signiﬁcant differences between groups.
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Blood pressure. We recorded continuous ambulatory
blood pressure proﬁles over 24 h, which were not affected
by resveratrol (Fig. 2). The tendency of resveratrol to in-
crease mean systolic (delta change 2.75 6 1.38 mmHg) as
well as mean diastolic (delta change 2.25 6 0.58 mmHg)
blood pressures was nonsigniﬁcant when compared with
the placebo group (systolic, P = 0.39; diastolic, P = 0.36).
Body composition. We did not demonstrate any signiﬁ-
cant differences in total body mass, lean body mass, total
body fat mass, or visceral and abdominal subcutaneous fat
volumes (Fig. 3).
Liver and skeletal muscle lipid content. Even though
considerable hepatic fat inﬁltration was evident at base-
line, no signiﬁcant changes occurred in either group during
the trial. The same was true when analyzing the intra-
myocellular lipid content (Fig. 4).
Gene expression and protein phosphorylation. Acti-
vation of AMP-activated protein kinase (AMPK) in the
muscle tissue biopsies by phosphorylation of the Thr172
residue of the catalytic a-subunit was not impacted by
resveratrol. Consistent with this, phosphorylation of acetyl-
CoA carboxylase, a well-known downstream target of
AMPK activity, also was not affected by the intervention.
Furthermore, we explored the proposed SIRT1-mediated
deacetylase activity potentially induced by resveratrol by
assessing the total acetylation status of lysine residues, which
also was not affected (Fig. 5 and Supplementary Fig. 4).
Apart from a slightly decreased insulin-stimulated ex-
pression of GLUT4 mRNA in muscle in the resveratrol
group, gene transcription in muscle and fat did not change
in any groups (Fig. 5 and Supplementary Fig. 4).
DISCUSSION
The main ﬁnding of our study is that short-term (4 weeks)
supplementation with high-dose resveratrol is not associ-
ated with detectable physiological effects in obese sub-
jects with modest insulin resistance. We consider this trial
important for several reasons. First, the high incidence of
obesity and type 2 diabetes calls for novel preventive and
therapeutic modalities. Second, substantial evidence from
preclinical work suggests that resveratrol stimulates SIRT1
activity and suppresses inﬂammatory pathways in human
adipose tissue in vitro (49,50). Third, the compound is al-
ready widely available as an over-the-counter nutritional
supplement with an array of alleged salutary effects.
Fourth, resveratrol treatment may serve as a model to in-
vestigate potential biomarkers for CR and SIRT1 in human
models.
Our primary outcome, insulin sensitivity, which was
assessed by the hyperinsulinemic euglycemic clamp, was
not signiﬁcantly affected by resveratrol. The same was true
for HOMA-IR, fasting glucose, and fasting insulin. Our
negative ﬁndings are in conﬂict with the work by Timmers
et al. (29), who demonstrated statistically signiﬁcant
improvements in HOMA-IR, suggesting a favorable effect
on insulin sensitivity. However, the gold standard for the
assessment of whole-body insulin sensitivity is the hyper-
insulinemic euglycemic clamp technique used in our study.
Furthermore, our inclusion of glucose tracer allowed for
the determination of glucose turnover in the basal state
and EGP during the clamp, all of which also failed to be
affected by resveratrol. We also found no effects of
resveratrol on either resting energy expenditure or rates of
lipid oxidation.
When assessing blood pressure, we found a trend to-
ward a moderate increase in 24-h blood pressure after
resveratrol administration compared with placebo. Again,
the differences were insigniﬁcant and in opposition to the
ﬁndings by Timmers et al. (29), who recorded a robust
decrease in both systolic and diastolic blood pressures,
which were assessed by the mean of conventional clinical
blood pressure triplicates. Furthermore, we examined the
ectopic fat content in hepatic and muscle tissue by MR
spectroscopy and, in contrast to Timmers et al., we recorded
no effects of resveratrol. In preclinical settings, the ﬁnding of
diminished hepatic fat induced by resveratrol is consistent,
and the reason why we fail to reproduce the ﬁndings by
Timmers et al. could relate to baseline differences. Because
lipid content is expressed as a relative number relative to the
water content, we cannot directly compare the data sets. In
accordance with the ectopic fat content, we also failed to
detect changes in adipose tissue assessed by MR imaging,
which perhaps is less surprising considering the relatively
short duration of treatment.
Consistent with the lack of physiological responses to
high-dose resveratrol, we also did not ﬁnd any alterations
in gene expression of a panel of pivotal metabolic and
FIG. 4. Ectopic lipid. Relative changes in ectopic lipid deposition from
baseline after 4 weeks of placebo or resveratrol supplementation, re-
spectively. Results are generated by 1H-MR spectroscopy and raw data
processing provides an estimate of the ratio of lipid to water (LWR)
within the tissue. The box boundaries indicate the 25th–75th percentile
range, and error bars represent the 5th–95th percentiles. Solid and
dotted lines represent median and mean, respectively. Two-way re-
peated-measures ANOVA revealed no statistically signiﬁcant differ-
ences between groups. A: Changes in hepatic lipid content; 11 were
evaluable in each group. B: Changes in intramyocellular lipid (IMCL)
content; 10 were evaluable in each group.
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FIG. 5. Gene expression and protein phosphorylation. Intracellular protein levels and relative mRNA expression in muscle (A–D) and adipose (E and
F) tissue biopsies taken before and after 4 weeks’ treatment with placebo (n = 12) or resveratrol (n = 12). Biopsies were taken before and during (20
min after initiation) a hyperinsulinemic euglycemic clamp. Black bars indicate the placebo group and white bars indicate the resveratrol group. Results
are presented as group means6 SEM, and overall comparisons of potential treatment effects were performed by two-way repeated-measures ANOVA in
the basal and clamp situations, respectively. A: Phosphorylation of the intracellular kinase AMP-activated protein kinase (AMPK) assessed by Western
blot analysis in muscle tissue. B: Total acetylation of lysine residues assessed by Western blot analysis in muscle tissue. C: Relative GLUT4 mRNA
expression in muscle tissue assessed by RT-PCR. D: Relative peroxisome proliferator-activated receptor g coactivator 1-a (PGC1a) mRNA expression
in muscle tissue assessed by RT-PCR. E: Relative tumor necrosis factor (TNF)-amRNA expression in subcutaneous adipose tissue assessed by RT-PCR.
F: Relative nuclear factor (NF)-kBmRNA expression in subcutaneous adipose tissue assessed by RT-PCR. *InC, we found an overall treatment effect in
the clamp situation, and a post hoc test revealed a statistically signiﬁcant (P < 0.05) decreased expression of GLUT4 in the resveratrol group.
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inﬂammatory biomarkers. Nor were protein phosphoryla-
tion levels of AMPK and acetyl-CoA carboxylase or total
acetylation status affected. As mentioned, our data dis-
agree with the recently published work by Timmers et al.
(29), who recorded signiﬁcant effects using only one-tenth
of our dose in a group of obese men. In comparison with
the participants in the study by Timmers et al., ours were
slightly younger (age 38.4 6 2.6 vs. 52.5 6 2.1 years) and
more obese (BMI 34.2 6 0.7 vs. 31.59 6 0.7 kg/m2; fat
31.3 6 0.8 vs. 26.4 6 0.5%). To what degree age and extent
of obesity may impact the effect of resveratrol in human
subjects remains to be investigated. We have scrutinized
our design to identify potential design-related problems to
explain the lack of effect. We have demonstrated that the
absorption of our resveratol formulation is comparable to
the absorption of the compound used in the study by
Timmers et al. Our study groups were well matched and of
a reasonable sample size, the compliance was good, and
we consider the duration of treatment sufﬁcient. The dif-
ference in age between our two treatment groups was due
to two outliers in the resveratrol group, aged 60 and 68
years. We have repeated all our analysis without these two
outliers, which did not change the negative outcome (data
not shown). Finally, the risk of a type 2 error due to low
sample size should also be considered. In the study by
Timmers et al., a sample size of 11 was sufﬁcient to dem-
onstrate effects in a cross-over design. Compared with that
study, ours holds the potential advantage of a parallel de-
sign, which eliminates the risk of untoward seasonal
changes and carry-over effects. A limitation of our study is
the inability to directly demonstrate the presence of res-
veratrol and metabolites in plasma. However, we demon-
strated the absorption and excretion of the investigational
product by means of our pharmacokinetic pilot study and
urinary metabolite measurements.
Based on solid preclinical evidence, it is likely that
a certain degree of baseline metabolic abnormalities is
a prerequisite to beneﬁt from resveratrol treatment, and it
could be speculated that our participants were “too
healthy.” However, both HOMA and M values at baseline
may indicate mild insulin resistance in our cohort: a HOMA
value of 2.77 previously has been deﬁned as the threshold
for insulin resistance in metabolically healthy subjects
(51). Moreover, in a group of lean but slightly younger men
(BMI, 24.66 3.2 kg/m2; age 23.06 2.0 years) clamped at an
identical insulin dose and with the same procedures as
those used in our laboratory, we recorded an M value of
5.8 mg/kg/min after 3 h (52) compared with 2.5 mg/kg/min
in the current study, which suggests a 60% reduction in
insulin sensitivity in our participants. Nonetheless, in fu-
ture studies, and before making any deﬁnitive conclusions,
the therapeutic potential of resveratrol should be tested in
patients with more pronounced morbidity such as type 2
diabetes, nonalcoholic fatty liver disease, and hyperten-
sion.
Little is known about the pharmacodynamic properties
of resveratrol. Even though the preclinical evidence is
quite substantial, basic mechanisms of action are not elu-
cidated or agreed upon. SIRT1 seems to be a pivotal
mediator of the metabolic effects of resveratrol, but the
up- and downstream mechanisms are not fully understood.
One of the main questions pending is whether the effects
depend on AMPK and, if so, whether AMPK activation is
up- or downstream of SIRT1. Regardless of our inability to
demonstrate AMPK activation, resveratrol may have po-
tential targets in addition to AMPK and SIRT1. Emerging
evidence suggests certain pathways are affected differ-
ently at different dose levels, with subsequent effects on
physiological outcomes, both in vitro (53) and in vivo (22).
In fact, to our knowledge, the latter work is the ﬁrst to
report an inverse dose-response relationship in vivo; more
pronounced effects apparently are observed at lower
doses. Even though an inverted or J-shaped dose-response
relationship seems to be an unlikely explanation for our
results, this remains a possibility. Future studies should
focus on dose-response relationships and preferably also
compare the impact of treatment duration, including po-
tential acute effects of resveratrol. It also remains to be
reported whether alternative small-molecule activators of
SIRT1 (STACs) may be more effective compared with
resveratrol in clinical settings. Regardless of our ﬁndings,
the scientiﬁc ﬁeld of sirtuin biology remains an area of
great interest.
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